Title:Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance
VOLUME: 20 ISSUE: 9
Author(s):Kajal Ghosal*, Christian Agatemor, Richard I. Han, Amy T. Ku, Sabu Thomas and Sudit Mukherjee
Affiliation:Dr. B.C. Roy College of Pharmacy and AHS, Durgapur 713206, Department of Biomedical Engineering, School of Medicine, John Hopkins University, Baltimore MD, 21231, Department of Bioengineering, Rice University, Houston TX, 77030, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston TX, 77030, International and Inter University Center for Nanoscience and Nanotechnology (IIUCNN), Mahatma Gandhi University, Priyadarshini Hill, Kottayam 686560, Kerala, Deparment of Biotechnology, National Institute of Technology, Durgapur
Keywords:Anti-cancer drugs, Fanconi anaemia pathway, Chemo-resistant cancer cells, Alternative treatment, Chemotherapy,
DNA.
Abstract:Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one
common obstacle to the success is the development of chemoresistance, which leads to failure of the
previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in
this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway
has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a
new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth
understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.